Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Boehringer Ingelheim
Colorcon
Harvard Business School

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021877

See Plans and Pricing

« Back to Dashboard

NDA 021877 describes ARRANON, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. Additional details are available on the ARRANON profile page.

The generic ingredient in ARRANON is nelarabine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelarabine profile page.
Summary for 021877
Tradename:ARRANON
Applicant:Novartis Pharms Corp
Ingredient:nelarabine
Patents:0
Pharmacology for NDA: 021877
Suppliers and Packaging for NDA: 021877
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877 NDA Novartis Pharmaceuticals Corporation 0078-0683 0078-0683-06 6 VIAL in 1 CARTON (0078-0683-06) > 50 mL in 1 VIAL
ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877 NDA Novartis Pharmaceuticals Corporation 0078-0683 0078-0683-61 50 mL in 1 VIAL (0078-0683-61)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength250MG/50ML (5MG/ML)
Approval Date:Oct 28, 2005TE:RLD:Yes

Expired US Patents for NDA 021877

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Mallinckrodt
McKesson
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.